Victory Capital Management Inc. Cuts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Victory Capital Management Inc. cut its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 40.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,687 shares of the biopharmaceutical company’s stock after selling 1,196,519 shares during the quarter. Victory Capital Management Inc. owned 0.60% of Amicus Therapeutics worth $24,871,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of FOLD. Bank of New York Mellon Corp increased its holdings in shares of Amicus Therapeutics by 0.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,182,107 shares of the biopharmaceutical company’s stock valued at $14,374,000 after purchasing an additional 5,808 shares in the last quarter. Brown Advisory Inc. increased its holdings in Amicus Therapeutics by 36.5% in the third quarter. Brown Advisory Inc. now owns 45,985 shares of the biopharmaceutical company’s stock valued at $559,000 after buying an additional 12,285 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Amicus Therapeutics by 11.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,327 shares of the biopharmaceutical company’s stock valued at $515,000 after acquiring an additional 4,508 shares during the period. Park Avenue Securities LLC purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter worth approximately $128,000. Finally, Assetmark Inc. grew its holdings in shares of Amicus Therapeutics by 24.1% in the 3rd quarter. Assetmark Inc. now owns 70,661 shares of the biopharmaceutical company’s stock worth $859,000 after acquiring an additional 13,725 shares during the period.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $10.14 on Thursday. Amicus Therapeutics, Inc. has a one year low of $9.70 and a one year high of $14.57. The stock has a market cap of $3.00 billion, a PE ratio of -19.88 and a beta of 0.80. The business’s fifty day moving average price is $11.35 and its two-hundred day moving average price is $11.98. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.52 and a current ratio of 2.88.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. The company had revenue of $115.08 million for the quarter, compared to analyst estimates of $115.11 million. On average, analysts forecast that Amicus Therapeutics, Inc. will post 0.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

FOLD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. decreased their target price on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Monday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a research note on Thursday, February 29th.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 4,167 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the sale, the chief executive officer now owns 871,219 shares in the company, valued at $12,197,066. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Bradley L. Campbell sold 4,167 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the transaction, the chief executive officer now directly owns 871,219 shares in the company, valued at $12,197,066. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,928,605.78. The disclosure for this sale can be found here. Insiders sold a total of 55,208 shares of company stock worth $732,930 over the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.